Business Context and Reporting Period
This Form 8-K Current Report was filed by MYOMO, INC. on March 1, 2024. The filing addresses a specific regulatory event regarding the Centers for Medicare and Medicaid Services (CMS) final fee schedule payment rates for the Company's MyoPro devices.
Key Financial Metrics
This filing does not contain standard financial statements, revenue, profit, cash flow, or debt metrics. The only financial data provided relates to specific reimbursement rates:
- L8701 (Motion W device): Final average fee schedule rate of $33,480.90.
- L8702 (Motion G device): Final average fee schedule rate of $65,871.74.
- Effective Date: These rates become effective on April 1, 2024.
Material Changes
The material change reported is the transition from proposed to final CMS fee schedule rates for the Company's devices. The final rates match the previously proposed average fee schedule rates announced by CMS.
Guidance, Outlook, and Risks
The filing includes a press release (Exhibit 99.1) but does not provide updated financial guidance, management commentary on future outlook, or specific risk factors beyond the context of the reimbursement announcement. No unusual items or contingencies are detailed in the text of this report.
Investor Verification Checklist
- Verify the impact of the new CMS rates ($33,480.90 and $65,871.74) on the Company's projected revenue starting April 1, 2024.
- Review the full text of the press release included as Exhibit 99.1 for additional context on adoption rates or market response.
- Confirm whether these final rates differ from any internal revenue assumptions previously disclosed by management.